All In Biotech

Drug Trial Radar · NCT02720094

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,570 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,570

Actual

Start

Dec 19, 2016

Primary completion

May 14, 2020

Study completion Mar 31, 2025

Sponsor

Sponsor type
NIH
Collaborators
ViiV Healthcare; Gilead Sciences
First posted
Mar 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).

Conditions

  • HIV Infections

Interventions

  • Cabotegravir Oral TabletDrug

    30 mg tablet

  • TDF/FTC tabletsDrug

    300 mg/200 mg fixed-dose combination tablets

  • Placebo for TDF/FTC tabletsDrug

  • Placebo for cabotegravir oral tabletDrug

  • CAB LADrug

    Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter

  • Placebo for CAB LADrug

    Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Documented Incident HIV Infections During Steps 1 and 2Time frame: HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.
  2. Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse EventsTime frame: Treatment emergent AE* measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks).

Locations

43 sites in 7 countries. Site status is shown where the registry gives one.

  • Alabama CRS

    Birmingham, Alabama

  • UCLA Vine Street Clinic CRS

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • East Bay AIDS Center (EBAC) CRS

    Oakland, California

  • Bridge HIV CRS

    San Francisco, California

  • Children's Hospital Colorado CRS

    Aurora, Colorado

  • George Washington Univ. CRS

    Washington D.C., District of Columbia

  • The Ponce de Leon Center CRS

    Atlanta, Georgia

  • The Hope Clinic of the Emory Vaccine Center CRS

    Decatur, Georgia

  • Adolescent & Young Adult Research at The CORE Center (AYAR at CORE)

    Chicago, Illinois

  • UIC Project WISH CRS

    Chicago, Illinois

  • New Orleans Adolescent Trials Unit CRS

    New Orleans, Louisiana

  • Johns Hopkins University CRS

    Baltimore, Maryland

  • Fenway Health (FH) CRS

    Boston, Massachusetts

  • Washington University Therapeutics (WT) CRS

    St Louis, Missouri

  • New Jersey Medical School Clinical Research Center CRS

    Newark, New Jersey

  • Weill Cornell Chelsea CRS

    New York, New York

  • Harlem Prevention Center CRS

    New York, New York

  • New York Blood Center CRS

    New York, New York

  • Bronx Prevention Research Center CRS

    The Bronx, New York

  • Chapel Hill CRS

    Chapel Hill, North Carolina

  • Greensboro CRS

    Greensboro, North Carolina

  • Cincinnati Clinical Research Site

    Cincinnati, Ohio

  • Ohio State University CRS

    Columbus, Ohio

  • Penn Prevention CRS

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital CRS

    Memphis, Tennessee

  • Houston AIDS Research Team CRS

    Houston, Texas

  • Fundacion Huesped CRS

    Buenos Aires, Argentina

  • Hospital General de Agudos JM Ramos Mejía CRS

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Rio de Janeiro, Brazil

  • Centro de Pesquisas Clínicas IC-HCFMUSP CRS

    São Paulo, Brazil

  • Hospital Nossa Senhora da Conceicao CRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Referencia e Treinamento DST/AIDS CRS

    São Paulo, São Paulo, Brazil

  • Via Libre CRS

    Lima, Peru

  • Barranco CRS

    Lima, Peru

  • San Miguel CRS

    Lima, Peru

  • ACSA CRS

    Iquitos, Maynas, Peru

  • CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS

    Bellavista, Provincia Constitucional del Callao, Peru

  • Groote Schuur HIV CRS

    Cape Town, Western Cape, South Africa

  • CMU HIV Prevention CRS

    Chiang Mai, Thailand

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.